4893 items matching your search terms.

Risk of treatment-related toxicities from EGFR tyrosine kinase inhibitors: a meta-analysis of clinical trials of gefitinib, erlotinib, and afatinib in advanced egfr-mutated non-small cell lung cancer

Ding, P. N. Lord, S. J. Gebski, V. Links, M. Bray, V. Gralla, R. J. Yang, J. C. Lee, C. K.
JOURNAL OF THORACIC ONCOLOGY, 2017     DOI:10.1016/j.jtho.2016.11.2236

Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis

Dobler, C. C. Cheung, K. Nguyen, J. Martin, A.
EUROPEAN RESPIRATORY JOURNAL, 2017     DOI:10.1183/13993003.00157-2017

The importance of censoring in competing risks analysis of the subdistribution hazard

Donoghoe, M. W. Gebski, V.
BMC MEDICAL RESEARCH METHODOLOGY, 2017     DOI:10.1186/s12874-017-0327-3

A guideline-based audit of hospital treatment practices in heart failure with reduced ejection fraction

Drak, D. Fulcher, J. Adams, D. Lattimore, J.D. Keech, A.

Predictors of incident heart failure in patients after an acute coronary syndrome: the LIPID heart failure risk-prediction model

Driscoll, A. Barnes, E. H. Blankenberg, S. Colquhoun, D. M. Hunt, D. Nestel, P. J. Stewart, R. A. West, M. J. White, H. D. Simes, J. Tonkin, A.
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017     DOI:10.1016/j.ijcard.2017.06.098

Incidence and mortality rates and clinical characteristics of type 1 diabetes among children and young adults in Cochabamba, Bolivia

Duarte Gomez, E. Gregory, G. A. Castrati Nostas, M. Middlehurst, A. C. Jenkins, A. J. Ogle, G. D.
J DIABETES RES, 2017     DOI:10.1155/2017/8454757

Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial

Duchesne, G. M. Woo, H. H. King, M. Bowe, S. J. Stockler, M. R. Ames, A. D'Este, C. Frydenberg, M. Loblaw, A. Malone, S. Millar, J. Tai, K. H. Turner, S.
LANCET ONCOLOGY, 2017     DOI:10.1016/S1470-2045(17)30426-6

Platinum-containing regimens for metastatic breast cancer

Egger, S. J. Willson, M. L. Morgan, J. Walker, H. S. Carrick, S. Ghersi, D. Wilcken, N.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017     DOI:10.1002/14651858.CD003374.pub4

ProCare Trial: a phase II randomized controlled trial of shared care for follow-up of men with prostate cancer

Emery, J. D. Jefford, M. King, M. Hayne, D. Martin, A. Doorey, J. Hyatt, A. Habgood, E. Lim, T. Hawks, C. Pirotta, M. Trevena, L. Schofield, P.
BJU INTERNATIONAL, 2017     DOI:10.1111/bju.13593

Do systematic reviews on pediatric topics need special methodological considerations?

Farid-Kapadia, M. Askie, L. Hartling, L. Contopoulos-Ioannidis, D. Bhutta, Z. A. Soll, R. Moher, D. Offringa, M.
BMC PEDIATRICS, 2017     DOI:10.1186/s12887-017-0812-1

Pelvic organ support several years after a first birth

Ferreira, C. W. S. Atan, I. K. Martin, A. Shek, K. L. Dietz, H. P.
, 2017     DOI:10.1007/s00192-017-3297-4

Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial

Field, K. M. Fitt, G. Rosenthal, M. A. Simes, J. Nowak, A. K. Barnes, E. H. Sawkins, K. Goh, C. Moffat, B. A. Salinas, S. Cher, L. Wheeler, H. Hovey, E. J. Phal, P. M. Cabaret Cogno Investigators
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017     DOI:10.1111/ajco.12806

Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma

Field, K. M. King, M. T. Simes, J. Espinoza, D. Barnes, E. H. Sawkins, K. Rosenthal, M. A. Cher, L. Hovey, E. Wheeler, H. Nowak, A. K.
JOURNAL OF NEURO-ONCOLOGY, 2017     DOI:10.1007/s11060-017-2479-8

The role of early magnetic resonance imaging in predicting survival on bevacizumab for recurrent glioblastoma: results from a prospective clinical trial (CABARET)

Field, K. M. Phal, P. M. Fitt, G. Goh, C. Nowak, A. K. Rosenthal, M. A. Simes, J. Barnes, E. H. Sawkins, K. Cher, L. M. Hovey, E. J. Wheeler, H.
CANCER, 2017     DOI:10.1002/cncr.30838

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis

Fisher, O. M. Lord, S. J. Falkenback, D. Clemons, N. J. Eslick, G. D. Lord, R. V.
GUT, 2017     DOI:10.1136/gutjnl-2015-310888